Management of Variceal Bleeding with Octreotide

Immediate Initiation Protocol

The American Association for the Study of Liver Diseases recommends starting octreotide immediately upon suspicion of variceal bleeding with a 50 μg intravenous bolus, followed by continuous infusion at 50 μg/hour, even before diagnostic endoscopy is performed 1, 2
Early administration of octreotide reduces mortality by 26% (relative risk 0.74) in patients with variceal hemorrhage, and should be initiated simultaneously with volume resuscitation and antibiotic prophylaxis, before the patient reaches the endoscopy suite 1, 2, 3

The initial IV bolus of octreotide should be 50 μg, which can be repeated once within the first hour if active bleeding continues, followed by a continuous IV infusion of 50 μg/hour starting immediately after the bolus 1, 2

The European Association for the Study of the Liver recommends ceftriaxone 1 g IV every 24 hours as first-line antibiotic prophylaxis in patients with advanced cirrhosis, those on quinolone prophylaxis, or in settings with high quinolone resistance, and should be continued for up to 7 days 1, 3
A restrictive transfusion strategy should be used, with transfusion at hemoglobin ≤7 g/dL, targeting 7-9 g/dL 3

The American College of Gastroenterology recommends continuing octreotide if endoscopy confirms variceal bleeding, and discontinuing it if endoscopy reveals non-variceal upper GI bleeding 1, 2
High-risk patients, such as those with Child-Pugh C with score ≤13 or Child-Pugh B with active bleeding at endoscopy despite vasoactive drugs, should be considered for early pre-emptive TIPS (within 24-72 hours) 1, 3

The American Association for the Study of Liver Diseases recommends initiating octreotide or somatostatin in pregnant patients with active variceal hemorrhage, as comprehensive management of life-threatening bleeding outweighs theoretical risks of splanchnic vasoconstriction 4
Octreotide is the only vasoactive drug available in the United States for variceal hemorrhage, and shows no significant differences in hemostatic efficacy or safety when used as adjuncts to endoscopic treatment compared to terlipressin and somatostatin 1, 2

The American Association for the Study of Liver Diseases recommends administering ceftriaxone 1g IV every 24 hours concurrently with octreotide for up to 7 days in patients with variceal bleeding, based on moderate quality evidence 5
Varicella bleeding complications are typically thrombocytopenic or coagulopathic in nature and require supportive care, not vasoactive drugs, according to the World Journal of Emergency Surgery 6

Octreotide must be combined with endoscopic variceal ligation (EVL) as first-line therapy, as octreotide alone is insufficient, and this combination significantly reduces recurrent bleeding from 38% to 9% when added to endoscopic variceal ligation (relative risk 0.22) 6, 7

In patients with anorectal varices, consider octreotide or terlipressin to reduce splanchnic blood flow and portal pressure, although this is a weak recommendation based on very low quality evidence 6, 7
Temporarily suspending beta-blockers during acute bleeding if the patient is hypotensive (systolic BP <90 mmHg or MAP <65 mmHg) is recommended, according to the World Journal of Emergency Surgery 6